Alaunos Therapeutics, Inc. (TCRT) filings document an early-stage biotechnology issuer with a developing small-molecule program, a legacy TCR-T oncology platform and a public-company capital structure. Form 8-K reports cover ALN1003 preclinical disclosures, material agreements, settlement matters, Nasdaq continued-listing notices, governance changes, director and officer transitions, and modifications to stockholder rights.
Registration statements, annual meeting reports and periodic-report references describe securities offerings, authorized common stock, stockholder voting results, operating and financial results, risk factors, and stockholders' equity used in Nasdaq compliance determinations.
Alaunos Therapeutics, Inc. reports that it has regained compliance with the continued listing requirements of the Nasdaq Capital Market. Nasdaq’s Listing Qualifications staff notified the company on August 19, 2025 that the matter is now closed.
The company had previously fallen out of compliance after reporting stockholders’ equity of $2.06 million in its Annual Report for the year ended December 31, 2024, below the $2.5 million minimum required under Nasdaq Listing Rule 5550(b)(1). In its Quarterly Report for the period ended June 30, 2025, Alaunos reported stockholders’ equity of $3.66 million, which met the rule’s threshold and restored compliance.
Form 4 filing for Alaunos Therapeutics, Inc. (TCRT) discloses that director Robert W. Postma received new equity awards on July 3, 2025.
- Restricted stock units (RSUs): 4,050 shares of common stock granted at $0.00 cost and vested immediately, increasing his direct holding to 33,133 shares.
- Stock options: Option to purchase 6,400 shares at an exercise price of $5.00 per share, expiring July 3, 2035. One-twelfth of the option vests monthly starting July 3, 2025; any remaining unvested portion fully vests just before the 2026 annual meeting.
- Indirect holdings: 62,416 shares held through WaterMill Asset Management Corp. and 24 shares in a spouse’s IRA.
The transactions are incentive-based grants rather than market purchases or sales, so they do not immediately affect public float or cash flows. However, they modestly increase insider ownership and further align the director’s interests with shareholders.
Form 4 highlights: Director Jaime Vieser received new equity awards from Alaunos Therapeutics (TCRT) on 07/03/2025.
- Restricted Stock Units (RSUs): 3,400 common shares granted and fully vested immediately. This raised Vieser’s directly held stock from 17,759 to 21,159 shares.
- Employee Stock Options: 6,400 options with a $5.00 exercise price and 07/03/2035 expiry. One-twelfth vests each month; any unvested balance vests immediately before the 2026 annual meeting.
- Total beneficial ownership after the grant: 21,159 shares held directly, 2,100 shares held indirectly through children, and 13,503 shares held indirectly via Brushwood LLC where Vieser is Manager.
The awards were issued at $0.00 cost for the RSUs and standard option pricing for the options, indicating compensation rather than an open-market purchase. While the absolute numbers are modest relative to typical public-company share counts, the filing shows continued equity-based alignment between the director and shareholders.
Alaunos Therapeutics (TCRT) filed a Form 4 disclosing an equity award to recently appointed CEO and director Holger Weis.
- Grant: 130,000 non-qualified stock options with a $5.02 exercise price.
- Vesting: 25 % vests immediately; the remaining 75 % vests in equal quarterly installments over three years starting 2 Oct 2025, contingent on continued employment.
- Expiration: Options are exercisable until 1 Jul 2035.
The award, issued under the company’s 2020 Equity Incentive Plan, increases Weis’s direct derivative holdings to 130,000 options. No common-stock transactions or sales were reported.
Director Jaime Vieser of Alaunos Therapeutics (TCRT) reported the acquisition of derivative securities in a Form 4 filing. On June 24, 2025, Vieser purchased 250 shares of Series A-2 Convertible Preferred Stock at $4.49 per share.
Key transaction details:
- The preferred stock is convertible to 55,679.29 shares of common stock
- The securities are held in direct ownership
- The preferred stock is perpetual with no expiration date
- Transaction code 'P' indicates an open market purchase
This insider purchase by a director could signal confidence in the company's future prospects. The convertible preferred stock provides potential upside exposure to common stock while offering preferred stockholder benefits.
Insider Trading Activity Report for Alaunos Therapeutics (TCRT) reveals significant transactions by Director Robert W. Postma. On June 24, 2025, Postma acquired 600 shares of Series A-2 Convertible Preferred Stock at $4.49 per share through WaterMill Asset Management Corp, convertible to 133,630.29 common shares.
Key holdings and transactions include:
- Direct ownership of 29,083 common shares, including recent acquisition of 20,804 shares at $2.92
- Indirect ownership through WaterMill Asset Management Corp of 33,333 common shares
- 500 Series A-1 Preferred Stock (convertible to 181,159 common shares) at $2.76
- Employee Stock Option for 3,737 shares at $10.30, vesting monthly through 2025
Notable ownership restrictions include a 4.99% beneficial ownership limit on converted preferred shares. The filing indicates continued insider investment in the company with diversified security types.
Alaunos Therapeutics (Nasdaq:TCRT) filed an 8-K disclosing a registered direct offering that closed on June 24 2025. The company sold 338,725 common shares at $3.36 and 271,674 pre-funded warrants at $3.359, generating gross proceeds of roughly $2.1 million before fees. Proceeds are earmarked for general corporate purposes, including capital expenditures and working capital. The Securities Purchase Agreement (Ex. 10.1) contains customary covenants; a legal opinion (Ex. 5.1) and a press release (Ex. 99.1) are also included. No other material operational changes were reported.